



an Open Access Journal by MDPI

In Silico and In Vitro Screening of Small Molecule Inhibitors

Guest Editors:

Dr. Usama Ammar

School of Applied Sciences,
Edinburgh Napier University,
Sighthill Campus, 9 Sighthill
Court, Edinburgh EH11 4BN, UK

Dr. Domiziana Masci

Department of Basic
Biotechnological Sciences,
Intensivological and
Perioperative Clinics, Catholic
University of the Sacred Heart,
Largo Francesco Vito 1, 00168
Rome, Italy

Message from the Guest Editors

This Special Issue aims to highlight the latest advances, challenges and applications of in silico tools and in vitro screening in the field of drug discovery of SMIs. We welcome the submission of research and review articles on advances in the drug discovery, design and development of biological target inhibitors against different disease models. Scientists from both academia and industry are invited to submit their manuscripts covering relevant topics, including the design and synthesis of novel chemical entities (NCEs), repurposing of approved drugs, cell-based or animal experiments and in silico computational approaches to elucidate future directions in drug discovery.

Deadline for manuscript
submissions:

5 November 2024

The main objective of this Special Issue is to provide a comprehensive overview of cutting-edge in silico and in vitro screening methodologies for the design and development of bioactive NCEs with therapeutic relevance across various disease contexts, with a specific focus on the elucidation of SMI–biological target interaction mechanisms by employing the synergistic strategy of combining computational with experimental approaches.



mdpi.com/si/202617

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com